297 related articles for article (PubMed ID: 31662214)
21. Targeting tyrosine kinase: Development of acridone - pyrrole - oxindole hybrids against human breast cancer.
Kaur M; Singh P
Bioorg Med Chem Lett; 2019 Jan; 29(1):32-35. PubMed ID: 30446310
[TBL] [Abstract][Full Text] [Related]
22. Benzoxazole-appended piperidine derivatives as novel anticancer candidates against breast cancer.
AboulWafa OM; Daabees HMG; El-Said AH
Bioorg Chem; 2023 May; 134():106437. PubMed ID: 36842320
[TBL] [Abstract][Full Text] [Related]
23. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis, anticancer evaluation, molecular docking and cell cycle analysis of 3-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine derivatives as potent histone lysine demethylases (KDM) inhibitors and apoptosis inducers.
Metwally NH; Mohamed MS; Ragb EA
Bioorg Chem; 2019 Jul; 88():102929. PubMed ID: 31015179
[TBL] [Abstract][Full Text] [Related]
26. Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors.
Lei H; Fan S; Zhang H; Liu YJ; Hei YY; Zhang JJ; Zheng AQ; Xin M; Zhang SQ
Eur J Med Chem; 2020 Jan; 186():111888. PubMed ID: 31787359
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and antiproliferative activity of novel polynuclear heterocyclic compounds derived from 2,3-diaminophenazine.
Mahran AM; Ragab SSh; Hashem AI; Ali MM; Nada AA
Eur J Med Chem; 2015 Jan; 90():568-76. PubMed ID: 25497130
[TBL] [Abstract][Full Text] [Related]
28. Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.
Xu P; Chu J; Li Y; Wang Y; He Y; Qi C; Chang J
Bioorg Med Chem; 2019 Oct; 27(20):114938. PubMed ID: 31488358
[TBL] [Abstract][Full Text] [Related]
29. Quinazolin-4(3
Mirgany TO; Abdalla AN; Arifuzzaman M; Motiur Rahman AFM; Al-Salem HS
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):2055-2067. PubMed ID: 34551654
[TBL] [Abstract][Full Text] [Related]
30. Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions.
Nan X; Li HJ; Fang SB; Li QY; Wu YC
Eur J Med Chem; 2020 May; 193():112241. PubMed ID: 32200199
[TBL] [Abstract][Full Text] [Related]
31. Synthesis, biological evaluation, and molecular modeling studies of new benzoxazole derivatives as PARP-2 inhibitors targeting breast cancer.
El-Ghobashy NM; El-Sayed SM; Shehata IA; El-Ashmawy MB
Sci Rep; 2022 Sep; 12(1):16246. PubMed ID: 36171229
[TBL] [Abstract][Full Text] [Related]
32. Novel Nicotinonitrile Derivatives Bearing Imino Moieties Enhance Apoptosis and Inhibit Tyrosine Kinase.
El-Hashash MA; El-Bordany EA; Marzouk MI; El-Naggar AM; Nawar TMS; El-Sayed WM
Anticancer Agents Med Chem; 2018; 18(11):1589-1598. PubMed ID: 29745342
[TBL] [Abstract][Full Text] [Related]
33. Synthesis, anticancer activity, toxicity evaluation and molecular docking studies of novel phenylaminopyrimidine-(thio)urea hybrids as potential kinase inhibitors.
Türe A; Kahraman DC; Cetin-Atalay R; Helvacıoğlu S; Charehsaz M; Küçükgüzel İ
Comput Biol Chem; 2019 Feb; 78():227-241. PubMed ID: 30579980
[TBL] [Abstract][Full Text] [Related]
34. Rational modification of semaxanib and sunitinib for developing a tumor growth inhibitor targeting ATP binding site of tyrosine kinase.
Kaur J; Kaur B; Singh P
Bioorg Med Chem Lett; 2018 Jan; 28(2):129-133. PubMed ID: 29208523
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and anticancer studies of novel aminobenzazolyl pyrimidines as tyrosine kinase inhibitors.
Chikhale R; Thorat S; Choudhary RK; Gadewal N; Khedekar P
Bioorg Chem; 2018 Apr; 77():84-100. PubMed ID: 29342447
[TBL] [Abstract][Full Text] [Related]
36. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
37. Heterocyclization of 2-(2-phenylhydrazono)cyclohexane-1,3-dione to Synthesis Thiophene, Pyrazole and 1,2,4-triazine Derivatives with Anti-Tumor and Tyrosine Kinase Inhibitions.
Mohareb RM; Alwan ES
Anticancer Agents Med Chem; 2020; 20(10):1209-1220. PubMed ID: 32156245
[TBL] [Abstract][Full Text] [Related]
38. Development of 2'-aminospiro [pyrano[3,2-c]quinoline]-3'-carbonitrile derivatives as non-ATP competitive Src kinase inhibitors that suppress breast cancer cell migration and proliferation.
Ramadan M; A M M Elshaier Y; Aly AA; Abdel-Aziz M; Fathy HM; Brown AB; Pridgen JR; Dalby KN; Kaoud TS
Bioorg Chem; 2021 Nov; 116():105344. PubMed ID: 34598088
[TBL] [Abstract][Full Text] [Related]
39. Identification of novel N
Qi B; Yang Y; He H; Yue X; Zhou Y; Zhou X; Chen Y; Liu M; Zhang A; Wei F
Eur J Med Chem; 2018 Feb; 146():368-380. PubMed ID: 29407963
[TBL] [Abstract][Full Text] [Related]
40. Eco-friendly sequential one-pot synthesis, molecular docking, and anticancer evaluation of arylidene-hydrazinyl-thiazole derivatives as CDK2 inhibitors.
El-Naggar AM; El-Hashash MA; Elkaeed EB
Bioorg Chem; 2021 Mar; 108():104615. PubMed ID: 33484942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]